Purdue collaboration announced
Eli Lilly and Company and Purdue University announced a collaboration last week related to life science research.
Lily will provide up to $52 million, with a focus on developing improved delivery of injectable medicines with the goals of reducing pain, decreasing the number of injections, and enabling better patient compliance and overall health. Another goal is to develop predictive models for success that reduces risks associated with investing in drug development, and more effectively predict outcomes of new therapies. Expansion to other areas is expected.
"This strategic agreement links our two organizations in a commitment to scientific research supporting the global needs of patients," said Andrew Dahlem, Ph.D., vice president, chief operating officer, Lilly Research Laboratories. "In addition, our collaboration strengthens our shared commitment to attract and retain the top engineering and technology talent in Indiana."